- +49 8153 9970930
- info@productsandfeatures.com
- Argelsrieder Feld 1a, 82234 Wessling, GERMANY
Menu
TricValve® - Transcatheter Bicaval Valve System
Now CE certified and commercially available!
TricValve® - Transcatheter Bicaval Valve System
TricValve® – Transcatheter Bicaval Valve System is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. The prostheses are implanted percutaneously into the superior and inferior vena cava without disturbing the native tricuspid valve. It is especially intended for use for patients at extreme risk or who are inoperable for open surgical therapy.
SUPERIOR VENA CAVA VALVE
- Available Sizes: 25 mm and 29 mm Valves
- Treatment Range SVC 25: superior vena cava from 22 mm to 31 mm
- Treatment Range SVC 29: superior vena cava from 27 mm to 34 mm
- Frame Height (at relaxed state) SVC 25: 67 mm
- Frame Height (at relaxed state) SVC 29: 69 mm
- Leaflet Material: Bovine pericardium
- Skirt Material: Bovine pericardium - long skirt to prevent para valvular leak (PVL)
- Frame Material: Nitinol
INFERIOR VENA CAVA VALVE
- Available Sizes: 31 mm and 35 mm valves
- Treatment Range IVC 31: inferior vena cava from 24 mm to 31 mm
- Treatment Range IVC 35: inferior vena cava from 28 mm to 35 mm
- Frame Height (at relaxed state) IVC 31: 65 mm
- Frame Height (at relaxed state) IVC 35: 65 mm
- Leaflet Material: Bovine pericardium
- Skirt Material: Bovine pericardium + PET - short skirt to prevent hepatic vein occlusion
- Frame Material: Nitinol
Further Information
Publications
- Lauten, A. et al. Heterotopic Valve Replacement as an Interventional Approach to Tricuspid Regurgitation. Journal of the American College of Cardiology. Volume 55, Issue 5, 2 February 2010, Pages 499-500
- Lauten, A. et al. Percutaneous Caval Stent Valve Implantation: Investigation of an Interventional Approach for Treatment of Tricuspid Regurgitation. European Heart Journal, Volume 31, Issue 10, May 2010, Pages 1274–1281
- Lauten, A. et al. Heterotopic Transcatheter Tricuspid Valve Implantation: First-In-Man Application of a Novel Approach to Tricuspid Regurgitation. European Heart Journal, Volume 32, Issue 10, May 2011, Pages 1207–1213
- Lauten, A. et al. Interventional Perspective of Tricuspid Regurgitation: Caval Valve Implantation from Preclinical Trials to First Human Application. Journal of the American College of Cardiology. Volume 59, Issue 13 Supplement, March 2012
- Figulla, H. R. et al. Transcatheter Implantation of Self-Expandable Vena Cava Valves for Treatment of Tricuspid Regurgitation: First-Human-Case Description. Journal of the American College of Cardiology. Volume 62, Issue 18 Supplement 1, October 2013
- Lauten, A. et al. Caval Valve Implantation for Treatment of Tricuspid Regurgitation: Post-Mortem Evaluation After Mid-Term Follow-Up. European Heart Journal, Volume 35, Issue 25, 1 July 2014, Page 1651
- Lauten, A. et al. Percutaneous Bicaval Valve Implantation for Transcatheter Treatment of Tricuspid Regurgitation: Clinical Observations and 12-Month Follow-Up. Circulation: Cardiovascular Interventions. 2014; 7:268–272
- Figulla, H. R. et al. Transcatheter Interventions for Tricuspid Regurgitation - Heterotopic Technology: TricValve®. EuroIntervention 2016; 12:Y116-Y118
- Figulla, H. R. et al. The Transcatheter Valve Technology Pipeline for Treatment of Adult Valvular Heart Disease. European Heart Journal, Volume 37, Issue 28, 21 July 2016, Pages 2226–2239
- Lauten, A. et al. Caval Valve Implantation for Treatment of Severe Tricuspid Regurgitation. Journal of the American College of Cardiology. Volume 71, Issue 10, March 2018
- O’Neill, B. P. Caval Valve Implantation: Are 2 Valves Better Than 1? Circulation: Cardiovascular Interventions. 2018;11
- Lauten, A. et al. Interventional Treatment of Severe Tricuspid Regurgitation: Early Clinical Experience in a Multicenter, Observational, First-in-Man Study. Circulation: Cardiovascular Interventions. 2018;11
Vienna Aortic
The Vienna Aortic Valve SE – Self-expandable Transcatheter Valve System is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery.
Stent Systems
The EFIL+ Sirolimus Eluting Stent System is a combination product comprised of two regulated components.
